HARP - CONSENSUS CO - Harpoon Therapeutics

Harpoon Therapeutics (HARP) is a reputable player in the targeted destruction of solid tumors using the TriTAC system. Business development relies on medical research results rather than economic cycles, with the current metric standing at . This daily price chart illustrates the asset's dynamics, whose prospects now depend on future late-stage trial reports, as the potential for acquisition by tech giants is already priced in by the market.

This indicator represents an aggregated summary of investment bank price targets, which determines the fundamental liquidity threshold and the fair value of the asset. An analysis of the analysts' median price target reveals undervaluation zones for Harpoon Therapeutics (HARP), where the value of trispecific antibodies and M&A potential become the primary drivers of capitalization in the absence of current revenue from clinical developments.